NEW YORK (GenomeWeb) – Illumina has submitted a companion diagnostic test it developed in conjunction with pharmaceutical company Amgen to the US Food and Drug Administration for pre-market approval, the company said this week.

The submission is just one example of the company's continued move into the oncology market, Illumina CEO and President Francis deSouza said during a conference call discussing the firm's third quarter 2016 results.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.